KR20180073555A - 변형된 탄저균 독소 방어 항원 - Google Patents

변형된 탄저균 독소 방어 항원 Download PDF

Info

Publication number
KR20180073555A
KR20180073555A KR1020187008131A KR20187008131A KR20180073555A KR 20180073555 A KR20180073555 A KR 20180073555A KR 1020187008131 A KR1020187008131 A KR 1020187008131A KR 20187008131 A KR20187008131 A KR 20187008131A KR 20180073555 A KR20180073555 A KR 20180073555A
Authority
KR
South Korea
Prior art keywords
amino acid
ser
asn
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187008131A
Other languages
English (en)
Korean (ko)
Inventor
시-후이 리우
스티븐 에이치 레플라
토마스 에이치 버그
알렉산더 엔 웨인
다이앤 이 피터스
지 리우
쾅-화 첸
Original Assignee
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 filed Critical 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Publication of KR20180073555A publication Critical patent/KR20180073555A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187008131A 2015-08-27 2016-08-25 변형된 탄저균 독소 방어 항원 Ceased KR20180073555A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562210771P 2015-08-27 2015-08-27
US62/210,771 2015-08-27
US201662323218P 2016-04-15 2016-04-15
US62/323,218 2016-04-15
PCT/US2016/048706 WO2017035359A1 (en) 2015-08-27 2016-08-25 Modified anthrax toxin protective antigen

Publications (1)

Publication Number Publication Date
KR20180073555A true KR20180073555A (ko) 2018-07-02

Family

ID=56943920

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187008131A Ceased KR20180073555A (ko) 2015-08-27 2016-08-25 변형된 탄저균 독소 방어 항원

Country Status (7)

Country Link
US (1) US10835593B2 (enExample)
EP (1) EP3341393B1 (enExample)
JP (1) JP6865211B2 (enExample)
KR (1) KR20180073555A (enExample)
CN (1) CN108350041A (enExample)
AU (1) AU2016311429C1 (enExample)
WO (1) WO2017035359A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180073555A (ko) 2015-08-27 2018-07-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 변형된 탄저균 독소 방어 항원
CA3119599A1 (en) 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Als treatment using induced regulatory t (itreg) cells
EP4150060A4 (en) * 2020-05-13 2024-06-19 Rapa Therapeutics, LLC TREATMENT OR PREVENTION OF PRO-INFLAMMATORY DISEASES OR CONDITIONS USING INDUCED REGULATORY T CELLS (IT)
JP7648075B2 (ja) * 2020-11-27 2025-03-18 株式会社ダイセル 融合タンパク質
CN117343942B (zh) * 2023-12-06 2024-02-13 南京市食品药品监督检验院 一种pagA重组蛋白及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214340B1 (en) 1999-09-24 2004-11-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2005090393A2 (en) * 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
US20100168012A1 (en) 2006-12-14 2010-07-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculatuture
CN101215568B (zh) 2008-01-18 2010-06-23 畿晋庆三联（北京）生物技术有限公司 抗炭疽多肽及其应用与制备方法
WO2014134187A1 (en) * 2013-02-26 2014-09-04 The Regents Of The University Of California Compositions and methods for the treatment of cancer
US9890369B2 (en) 2013-06-20 2018-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
SG11201602012RA (en) 2013-09-25 2016-04-28 Pronutria Inc Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
KR20180073555A (ko) 2015-08-27 2018-07-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 변형된 탄저균 독소 방어 항원

Also Published As

Publication number Publication date
JP2018527926A (ja) 2018-09-27
EP3341393A1 (en) 2018-07-04
US10835593B2 (en) 2020-11-17
AU2016311429A1 (en) 2018-04-19
WO2017035359A1 (en) 2017-03-02
AU2016311429C1 (en) 2021-10-07
US20180250376A1 (en) 2018-09-06
CN108350041A (zh) 2018-07-31
JP6865211B2 (ja) 2021-04-28
AU2016311429B2 (en) 2021-07-08
CA2996767A1 (en) 2017-03-02
EP3341393B1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
EP1451322B1 (en) Il-21 antagonists
JP6133209B2 (ja) 抗ｓｓｘ−２ｔ細胞受容体及び関連材料並びに使用方法
EP3013854B1 (en) Cd86 variants with improved affinity for ctla-4
AU2019379325B2 (en) Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor
KR20200119891A (ko) Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거(elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells)
EP3341393B1 (en) Modified anthrax toxin protective antigen
CN113286615A (zh) 用于治疗癌症的微生物和免疫调节剂的组合疗法
WO2008014612A1 (en) Fusion proteins and methods for modulation of immune response
HUP0004611A2 (hu) APRIL, egy új növekedési hatású fehérje
JP2006514601A (ja) ガンおよびその他の治療用途におけるｉｌ−２１の使用方法
CA2366921A1 (en) Novel cytokine zalpha11 ligand
IL174175A (en) Use of an il-21 polypeptide for the preparation of pharmaceutical composition for decreasing cd4+ t-cell autoimmune response in a mammal
CN111420032A (zh) 用于治疗肿瘤的方法
US20090035258A1 (en) Methods of treating cancer by administering human il-18 combinations
US20050255083A1 (en) Multimeric protein toxins to target cells having multiple identifying characteristics
KR20220150274A (ko) Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법
EP2931293B1 (en) Compositions and methods for regulating erythropoiesis
CN119630400A (zh) 小分子药物缀合物与表达car的细胞毒性淋巴细胞的组合及使用方法
CA2996767C (en) Modified anthrax toxin protective antigen
RU2258710C2 (ru) Новый цитокин zalpha11-лиганд
WO2024214083A1 (en) Use of immunomodulation methods in combination with cytokine fusions for disease treatment
CN101641116A (zh) 通过施用人il-18组合来治疗癌症的方法
KR20140021485A (ko) 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180322

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210825

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240321

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240524

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20240321

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I